Shares of Rallybio Co. (NASDAQ:RLYB – Get Free Report) have been given a consensus rating of “Moderate Buy” by the six ratings firms that are currently covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1 year price target among analysts that have issued ratings on the stock in the last year is $12.20.
Several equities research analysts have recently weighed in on the company. Wedbush reduced their price objective on Rallybio from $13.00 to $11.00 and set an “outperform” rating for the company in a research report on Thursday, April 11th. Jefferies Financial Group cut Rallybio from a “buy” rating to a “hold” rating in a research report on Wednesday, February 7th. HC Wainwright reduced their price objective on Rallybio from $12.00 to $9.00 and set a “buy” rating for the company in a research report on Wednesday, March 13th. Finally, JMP Securities reissued a “market outperform” rating and issued a $8.00 price objective on shares of Rallybio in a research report on Thursday, April 18th.
Get Our Latest Research Report on Rallybio
Institutional Inflows and Outflows
Rallybio Stock Down 9.2 %
Shares of Rallybio stock opened at $1.58 on Monday. The stock has a market capitalization of $59.74 million, a P/E ratio of -0.86 and a beta of -1.64. The stock has a 50 day moving average price of $1.81 and a two-hundred day moving average price of $2.28. Rallybio has a 12-month low of $1.23 and a 12-month high of $9.14.
Rallybio (NASDAQ:RLYB – Get Free Report) last announced its earnings results on Tuesday, March 12th. The company reported ($0.50) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.44) by ($0.06). Sell-side analysts anticipate that Rallybio will post -1.6 earnings per share for the current year.
Rallybio Company Profile
Rallybio Corporation, a clinical-stage biotechnology company, engages in development and commercialization of life-transforming therapies for patients suffering from severe and rare diseases. Its lead product candidate is RLYB212, a monoclonal anti-HPA-1a antibody that has completed Phase I clinical trial for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT); and RLYB211 for the prevention of FNAIT.
Recommended Stories
- Five stocks we like better than Rallybio
- What is Forex and How Does it Work?
- High-Yield Texas Instruments Could Hit New Highs Soon
- Financial Services Stocks Investing
- Pagaya Technologies: An AI Fintech That Insiders Are Buying
- What to Know About Investing in Penny Stocks
- Higher Oil Prices Could Give NextEra’s Stock Earnings a Boost
Receive News & Ratings for Rallybio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rallybio and related companies with MarketBeat.com's FREE daily email newsletter.